

## **Materials Design Analysis Reporting (MDAR) Checklist for Authors**

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: [doi:10.31222/osf.io/9sm4x](https://doi.org/10.31222/osf.io/9sm4x)). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

**Materials**

|                                                                                                                                                                                                         |                                                         |            |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|------------|
| <b>Antibodies</b>                                                                                                                                                                                       | <b>Yes (indicate where provided: section/paragraph)</b> | <b>n/a</b> |
| For commercial reagents, provide supplier name, catalogue number and RRID, if available.                                                                                                                | <b>Methods /paragraph 6-7</b>                           |            |
| <b>Cell materials</b>                                                                                                                                                                                   | <b>Yes (indicate where provided: section/paragraph)</b> | <b>n/a</b> |
| <b>Cell lines:</b> Provide species information, strain. Provide accession number in repository <b>OR</b> supplier name, catalog number, clone number, <b>OR</b> RRID                                    | <b>Methods /paragraph 6</b>                             |            |
| <b>Primary cultures:</b> Provide species, strain, sex of origin, genetic modification status.                                                                                                           |                                                         | <b>n/a</b> |
| <b>Experimental animals</b>                                                                                                                                                                             | <b>Yes (indicate where provided: section/paragraph)</b> | <b>n/a</b> |
| <b>Laboratory animals:</b> Provide species, strain, sex, age, genetic modification status. Provide accession number in repository <b>OR</b> supplier name, catalog number, clone number, <b>OR</b> RRID |                                                         | <b>n/a</b> |
| <b>Animal observed in or captured from the field:</b> Provide species, sex and age where possible                                                                                                       |                                                         | <b>n/a</b> |
| <b>Model organisms:</b> Provide Accession number in repository (where relevant) <b>OR</b> RRID                                                                                                          |                                                         | <b>n/a</b> |
| <b>Plants and microbes</b>                                                                                                                                                                              | <b>Yes (indicate where provided: section/paragraph)</b> | <b>n/a</b> |
| <b>Plants:</b> provide species and strain, unique accession number if available, and source (including location for collected wild specimens)                                                           |                                                         | <b>n/a</b> |
| <b>Microbes:</b> provide species and strain, unique accession number if available, and source                                                                                                           |                                                         | <b>n/a</b> |
| <b>Human research participants</b>                                                                                                                                                                      | <b>Yes (indicate where provided: section/paragraph)</b> | <b>n/a</b> |
| Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.                                                                                     | <b>Methods /paragraph 1</b>                             |            |
| Provide statement confirming informed consent obtained from study participants.                                                                                                                         | <b>Methods /paragraph 1</b>                             |            |
| Report on age and sex for all study participants.                                                                                                                                                       |                                                         | <b>n/a</b> |

**Design**

|                                                                                                                                                                     |                                                         |            |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|------------|
| <b>Study protocol</b>                                                                                                                                               | <b>Yes (indicate where provided: section/paragraph)</b> | <b>n/a</b> |
| For clinical trials, provide the trial registration number <b>OR</b> cite DOI in manuscript.                                                                        |                                                         | <b>n/a</b> |
| <b>Laboratory protocol</b>                                                                                                                                          | <b>Yes (indicate where provided: section/paragraph)</b> | <b>n/a</b> |
| Provide DOI or other citation details if detailed step-by-step protocols are available.                                                                             |                                                         | <b>n/a</b> |
| <b>Experimental study design (statistics details)</b>                                                                                                               | <b>Yes (indicate where provided: section/paragraph)</b> | <b>n/a</b> |
| State whether and how the following have been done, <b>or</b> if they were not carried out.                                                                         |                                                         |            |
| Sample size determination                                                                                                                                           | <b>Methods /paragraph 1</b>                             |            |
| Randomisation                                                                                                                                                       | <b>Methods /paragraph 1</b>                             |            |
| Blinding                                                                                                                                                            |                                                         | <b>n/a</b> |
| Inclusion/exclusion criteria                                                                                                                                        | <b>Methods /paragraph 1</b>                             |            |
| <b>Sample definition and in-laboratory replication</b>                                                                                                              | <b>Yes (indicate where provided: section/paragraph)</b> | <b>n/a</b> |
| State number of times the experiment was replicated in laboratory                                                                                                   | <b>Methods /paragraph 12</b>                            |            |
| Define whether data describe technical or biological replicates                                                                                                     |                                                         | <b>n/a</b> |
| <b>Ethics</b>                                                                                                                                                       | <b>Yes (indicate where provided: section/paragraph)</b> | <b>n/a</b> |
| Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.   | <b>Methods /paragraph 1</b>                             |            |
| Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. |                                                         | <b>n/a</b> |
| Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why. | <b>Methods /paragraph 1</b>                             |            |
| <b>Dual Use Research of Concern (DURC)</b>                                                                                                                          | <b>Yes (indicate where provided: section/paragraph)</b> | <b>n/a</b> |
| If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval                         |                                                         | <b>n/a</b> |

**Analysis**

|                                                                                                                                               |                                                         |            |
|-----------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|------------|
| <b>Attrition</b>                                                                                                                              | <b>Yes (indicate where provided: section/paragraph)</b> | <b>n/a</b> |
| State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance. |                                                         | n/a        |
| <b>Statistics</b>                                                                                                                             | <b>Yes (indicate where provided: section/paragraph)</b> | <b>n/a</b> |
| Describe statistical tests used and justify choice of tests.                                                                                  | <b>Methods /paragraph 12</b>                            |            |
| <b>Data Availability</b>                                                                                                                      | <b>Yes (indicate where provided: section/paragraph)</b> | <b>n/a</b> |
| State whether newly created datasets are available, including protocols for access or restriction on access.                                  | 10.6084/m9.figshare.21377976                            |            |
| If data are publicly available, provide accession number in repository or DOI or URL.                                                         | 10.6084/m9.figshare.21377976                            |            |
| If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.                                  | 10.6084/m9.figshare.21377976                            |            |
| <b>Code Availability</b>                                                                                                                      | <b>Yes (indicate where provided: section/paragraph)</b> | <b>n/a</b> |
| For all newly generated code and software essential for replicating the main findings of the study:                                           |                                                         |            |
| State whether the code or software is available.                                                                                              | 10.6084/m9.figshare.21377976                            |            |
| If code is publicly available, provide accession number in repository, or DOI or URL.                                                         | 10.6084/m9.figshare.21377976                            |            |

**Reporting**

|                                                                                                                                                                                                                                          |                                                                                               |            |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|------------|
| <b>Adherence to community standards</b>                                                                                                                                                                                                  | <b>Yes (indicate where provided: section/paragraph)</b>                                       | <b>n/a</b> |
| MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR. |                                                                                               |            |
| State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.                                                                     | ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication. |            |

Article information: <https://dx.doi.org/10.21037/jtd-23-395>

## TRIPOD Checklist: Prediction Model Development and Validation

| Section                   | Item |     | Checklist description                                                                                                                                                                            | Reported on Page Number/Line Number | Reported on Section/Paragraph |
|---------------------------|------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|-------------------------------|
| <b>Title and abstract</b> |      |     |                                                                                                                                                                                                  |                                     |                               |
| Title                     | 1    | D;V | Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.                                                     | Page 1/Line 1                       | Title/Paragraph 1             |
| Abstract                  | 2    | D;V | Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.                                          | Page 2/Line 1-26                    | Abstract/Paragraph 1-5        |
| <b>Introduction</b>       |      |     |                                                                                                                                                                                                  |                                     |                               |
| Background and objectives | 3a   | D;V | Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models. | Page 2/Line 27-29; Page 3/Line 1-10 | Introduction/Paragraph 1      |
|                           | 3b   | D;V | Specify the objectives, including whether the study describes the development or validation of the model or both.                                                                                | Page 3/Line 11-21                   | Introduction/Paragraph 2      |
| <b>Methods</b>            |      |     |                                                                                                                                                                                                  |                                     |                               |
| Source of data            | 4a   | D;V | Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.                          | Page 3/Line 18-32                   | Methods/Paragraph 1           |
|                           | 4b   | D;V | Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.                                                                                   | Page 3/Line 18-32                   | Methods/Paragraph 1           |
| Participants              | 5a   | D;V | Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.                                                     | Page 4/Line 106-108                 | Methods/Paragraph 1           |
|                           | 5b   | D;V | Describe eligibility criteria for participants.                                                                                                                                                  | Page 4/Line 106-107                 | Methods/Paragraph 1           |
|                           | 5c   | D;V | Give details of treatments received, if relevant.                                                                                                                                                | Page 4/Line 106                     | Methods/Paragraph 1           |
| Outcome                   | 6a   | D;V | Clearly define the outcome that is predicted by the prediction model, including how and when assessed.                                                                                           | N/A                                 | N/A                           |
|                           | 6b   | D;V | Report any actions to blind assessment of the outcome to be predicted.                                                                                                                           | N/A                                 | N/A                           |
| Predictors                | 7a   | D;V | Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.                                                    | Page 4/Line 136                     | Methods/Paragraph 3           |
|                           | 7b   | D;V | Report any actions to blind assessment of predictors for the outcome and other predictors.                                                                                                       | N/A                                 | N/A                           |
| Sample size               | 8    | D;V | Explain how the study size was arrived at.                                                                                                                                                       | Page 4/Line 13-34                   | Methods/Paragraph 3           |

|                              |     |     |                                                                                                                                                                                                       |                     |                         |
|------------------------------|-----|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|-------------------------|
| Missing data                 | 9   | D;V | Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.                                                  | Page 3/Line 97-102  | Methods/Paragraph 1     |
| Statistical analysis methods | 10a | D   | Describe how predictors were handled in the analyses.                                                                                                                                                 | Page 8/Line 1-3     | Methods/Paragraph 12    |
|                              | 10b | D   | Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.                                                                         | Page 4/Line 122-136 | Methods/Paragraph 3     |
|                              | 10c | V   | For validation, describe how the predictions were calculated.                                                                                                                                         | Page 4/Line 106-108 | Methods/Paragraph 1     |
|                              | 10d | D;V | Specify all measures used to assess model performance and, if relevant, to compare multiple models.                                                                                                   | Page 4/Line 115-119 | Methods/Paragraph 2     |
|                              | 10e | V   | Describe any model updating (e.g., recalibration) arising from the validation, if done.                                                                                                               | N/A                 | N/A                     |
| Risk groups                  | 11  | D;V | Provide details on how risk groups were created, if done.                                                                                                                                             | N/A                 | N/A                     |
| Development vs. validation   | 12  | V   | For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.                                                                         | Page 4/Line 129-132 | Methods/Paragraph 3     |
| <b>Results</b>               |     |     |                                                                                                                                                                                                       |                     |                         |
| Participants                 | 13a | D;V | Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful. | Page 8/Line 254-257 | Results/Paragraph 1     |
|                              | 13b | D;V | Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.    | Page 8/Line 255-256 | Results/Paragraph 1     |
|                              | 13c | V   | For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).                                                        | Page 8/Line 254-257 | Results/Paragraph 1     |
| Model development            | 14a | D   | Specify the number of participants and outcome events in each analysis.                                                                                                                               | Page 8/Line 255-256 | Results/Paragraph 1     |
|                              | 14b | D   | If done, report the unadjusted association between each candidate predictor and outcome.                                                                                                              | N/A                 | N/A                     |
| Model specification          | 15a | D   | Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).                           | Page 8/Line 260-272 | Results/Paragraph 2     |
|                              | 15b | D   | Explain how to use the prediction model.                                                                                                                                                              | Page 8/Line 260-272 | Results/Paragraph 2     |
| Model performance            | 16  | D;V | Report performance measures (with CIs) for the prediction model.                                                                                                                                      | Page 8/Line 262-264 | Results/Paragraph 2     |
| Model-updating               | 17  | V   | If done, report the results from any model updating (i.e., model specification, model performance).                                                                                                   | N/A                 | N/A                     |
| <b>Discussion</b>            |     |     |                                                                                                                                                                                                       |                     |                         |
| Limitations                  | 18  | D;V | Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).                                                                                      | Page 11 /Line 22-30 | Conclusions/Paragraph 1 |

|                           |     |     |                                                                                                                                                    |                    |                         |
|---------------------------|-----|-----|----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-------------------------|
| Interpretation            | 19a | V   | For validation, discuss the results with reference to performance in the development data, and any other validation data.                          | N/A                | N/A                     |
|                           | 19b | D;V | Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence. | Page11 /Line22-30  | Conclusions/Paragraph 1 |
| Implications              | 20  | D;V | Discuss the potential clinical use of the model and implications for future research.                                                              | Page11 /Line22-30  | Conclusions/Paragraph   |
| <b>Other information</b>  |     |     |                                                                                                                                                    |                    |                         |
| Supplementary information | 21  | D;V | Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.                      | Page 3/Line 21 -34 | Methods/Paragraph 1     |
| Funding                   | 22  | D;V | Give the source of funding and the role of the funders for the present study.                                                                      | Page 1;12/Line     | Title page/Paragraph 4  |

\* Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.

Article information: <https://dx.doi.org/10.21037/jtd-23-395>

\*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.